JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Monash University
Melbourne, AustraliaPublicaciones en colaboración con investigadores/as de Monash University (4)
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45
2023
2017
-
Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 35, Núm. 1, pp. 40-47